Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Optos, PLC
Age
22–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
1. Subjects 22 years of age or older on the date of informed consent
2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
3. Subjects with normal eye examinations in both eyes on the date of the study visit as observed with a 90 diopter lens
4. BCVA 20/40 or better (each eye) on the date of the study visit
9. Subjects 22 years of age or older on the date of informed consent
10. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
11. BCVA 20/40 or better in the study eye
12. History of Visual field defects within the previous six (6) months from the study visit or measured the day of the study visit consistent with glaucomatous optic nerve damage with at least one of the following two findings:
1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;
2. Glaucoma hemi-field test "outside normal limits."
13. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities:
1. Diffuse thinning, focal narrowing, or notching of the neuroretinal rim, especially at the inferior or superior poles with or without disc hemorrhage;
2. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue
19. Subjects 22 years of age or older on the date of informed consent
20. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
21. Subjects presenting at the site with retinal disease
22. BCVA 20/400 or better in the study eye
23. Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration (including patients with drusen and geographic atropy and choroidal neovascularization), Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Central Serous Retinopathy and others
You may not be if
5. Subjects unable to tolerate ophthalmic imaging
6. Subjects with ocular media not sufficiently clear to obtain acceptable OCT images in either eye
7. Presence of any ocular pathology except for cataract in either eye
8. History of leukemia, dementia or multiple sclerosis
14. Subjects unable to tolerate ophthalmic imaging
15. Subjects with ocular media not sufficiently clear to obtain acceptable OCT images in the study eye
16. No reliable Humphrey Field Analyzer (HFA) visual field (24-2 Sita Standard, white on white) result within 6 months of the study visit, defined as fixation losses \> 33% or false positives \> 33%, or false negatives \> 33% in the study eye
17. Presence of any ocular pathology except glaucoma in the study eye
18. History of leukemia, dementia or multiple sclerosis
24. Subjects unable to tolerate ophthalmic imaging
25. Subject with ocular media not sufficiently clear to obtain acceptable OCT images in the study eye
26. Presence of glaucoma or any ocular pathology other than a retinal pathology (e.g., cornea pathology) in the study eye as determined by self-report and/or investigator assessment at the study visit;
27. History of leukemia, dementia or multiple sclerosis
